Free Trial

Echelon Wealth Partners' Rating of Oncolytics Biotech on 6/16/2020

On June 16, 2020, Echelon Wealth Partners updated its outlook on Oncolytics Biotech (NASDAQ:ONCY) with the action "Reiterated Rating", keeping a "Speculative Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.